4.6 Review

Chemobrain in Breast Cancer: Mechanisms, Clinical Manifestations, and Potential Interventions

Journal

DRUG SAFETY
Volume 45, Issue 6, Pages 601-621

Publisher

ADIS INT LTD
DOI: 10.1007/s40264-022-01182-3

Keywords

-

Funding

  1. National Council for Scientific and Technological Development (CNPq) [150654/2020-0, 305343/2019-0]
  2. FAPERGS [18.2551.0000513-4]

Ask authors/readers for more resources

Chemotherapy-related cognitive impairment (CRCI) has become a focus of research in the past years due to its potential adverse effects on breast cancer patients. This review provides an overview of the molecular mechanisms linking individual drugs used in breast cancer treatment to CRCI, the clinical characteristics of CRCI in patients, and possible therapeutic interventions. The incidence rates of CRCI in breast cancer vary considerably and may affect more than 50% of treated patients. Although there is currently no standard treatment for CRCI, various pharmacological and non-pharmacological approaches have shown promising results.
Among the potential adverse effects of breast cancer treatment, chemotherapy-related cognitive impairment (CRCI) has gained increased attention in the past years. In this review, we provide an overview of the literature regarding CRCI in breast cancer, focusing on three main aspects. The first aspect relates to the molecular mechanisms linking individual drugs commonly used to treat breast cancer and CRCI, which include oxidative stress and inflammation, reduced neurogenesis, reduced levels of specific neurotransmitters, alterations in neuronal dendrites and spines, and impairment in myelin production. The second aspect is related to the clinical characteristics of CRCI in patients with breast cancer treated with different drug combinations. Data suggest the incidence rates of CRCI in breast cancer vary considerably, and may affect more than 50% of treated patients. Both chemotherapy regimens with or without anthracyclines have been associated with CRCI manifestations. While cross-sectional studies suggest the presence of symptoms up to 20 years after treatment, longitudinal studies confirm cognitive impairments lasting for at most 4 years after the end of chemotherapy. The third and final aspect is related to possible therapeutic interventions. Although there is still no standard of care to treat CRCI, several pharmacological and non-pharmacological approaches have shown interesting results. In summary, even if cognitive impairments derived from chemotherapy resolve with time, awareness of CRCI is crucial to provide patients with a better understanding of the syndrome and to offer them the best care directed at improving quality of life.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available